Via press release from the CDC:
Today, the FDA approved an important new treatment for chronic hepatitis C. The drug, sofosbuvir, is a major advance in the treatment of a disease that affects approximately 3 million Americans and causes more than 15,000 deaths in the U.S. annually. Today marks a landmark advance in the treatment of hepatitis C, opening up new opportunities to stop the spread of this virus and the ravages of this disease. However, new therapies only work if people receive treatment – the potential of these and other treatment advances hinges entirely on our ability to get more people screened and into care. Right now, most Americans with hepatitis C don’t access treatment because they have no idea they’re infected.
Labels: CDC, FDA, Hep C, medicine, science
